ROTABLATOR™ and ROTAPRO™ Rotational Atherectomy Systems
Features the front-cutting, stable rotation of a diamond-tipped burr recognized by physicians as an optimal device to ablate calcium in coronary arteries.
Calcium Prevalence & Rotational Atherectomy
Calcium Impacts Long-Term Outcomes
Pooled analysis from the HORIZONS-AMI and ACUITY Trials suggests patients with moderate/severe calcium have a significantly higher chance of death, TLR, and MACE.1
HORIZONS-AMI & ACUITY Trials
1-Year Ischemic Outcomes
Data Supports Rotational Atherectomy
A 2015 large, multicenter registry evaluated the outcomes of patients undergoing rotational atherectomy (RA) in 9 major Australian hospitals over an 8-year period (16,410 non-RA PCIs, 167 RA PCIs).3
In the RA cohort:
- Patients were more likely to be older with a higher prevalence of comorbidities
- Patients were more likely to have complex type B2 and C lesions
- 37% of patients had a previously failed PCI
These patients represented the most complex of the PCI population where no other interventional therapy was an option.
Study Findings: Rotational atherectomy was safe and effective in resistant lesions
In Hospital Clinical Outcome:
No significant difference in angiographic success, dissections, perforations, or no reflow
1-Year Clinical Outcome:
No significant difference in MACE or TLR*
When lesions treated with DES(excluding bare metal stents) were isolated, analysis of the multicenter registry revealed a TLR rate of 2.9%.
- Rotational atherectomy is an important tool for treating complex lesions, with low procedural complications and MACE rates.
- Despite the significantly more difficult patient population, there were no significant differences in procedural complications.
- Given the excellent results, an upfront rotational atherectomy strategy for treating calcium has the potential to:
- Shorten procedure time
- Reduce number of overall procedures
- Reduce risks to patients
The C-code used for this product is C1724, catheter, transluminal atherectomy, rotational. C-codes are used for hospital outpatient device reporting for Medicare and some private payers.
Note: Boston Scientific is not responsible for the correct use of codes on submitted claims; this information does not constitute reimbursement or legal advice.